Tobin C. Schilke
2020 - Revance Therapeutics
Compensation breakdown
| Non-Equity Incentive Plan | $143,186 |
|---|---|
| Option Awards | $1,273,662 |
| Salary | $421,375 |
| Stock Awards | $1,131,345 |
| Other | $11,531 |
| Total | $2,981,099 |
Schilke received $1.3M in option awards, accounting for 43% of the total pay in 2020.
Schilke also received $143.2K in non-equity incentive plan, $421.4K in salary, $1.1M in stock awards and $11.5K in other compensation.
Rankings
In 2020, Tobin C. Schilke's compensation ranked 3,873rd out of 13,090 executives tracked by ExecPay. In other words, Schilke earned more than 70.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,873 out of 13,090 | 70th |
Division Manufacturing | 1,543 out of 5,624 | 73rd |
Major group Chemicals And Allied Products | 583 out of 2,257 | 74th |
Industry group Drugs | 502 out of 1,957 | 74th |
Industry Pharmaceutical Preparations | 379 out of 1,462 | 74th |
Pay ratio
| Tobin C. Schilke's Pay | $2,981,099 |
|---|---|
| Median Employee's Pay | $254,090 |
| Pay Ratio | 12to 1 |
In 2020, the annual total compensation of Tobin C. Schilke was $2,981,099.
The annual total compensation of the median employee at Revance Therapeutics was $254,090.
The ratio of Tobin C. Schilke's pay to the pay of median employee was therefore 12 to one.
Schilke's colleagues
We found four more compensation records of executives who worked with Tobin C. Schilke at Revance Therapeutics in 2020.
News
March 24, 2022
March 11, 2021
March 26, 2020
March 25, 2019